Karine Tremblay

Dr. Karine Tremblay

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DGDaniel Gaudet
Daniel Gaudet
VAVeronica J. Alexander
Veronica J. Alexander
BBBrenda F. Baker
Brenda F. Baker
DBDiane Brisson
Diane Brisson
KTKarine Tremblay
Karine Tremblay
JKJohn Jacob Pieter Kastelein
John Jacob Pieter Kastelein
Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis.

4 December 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DGDaniel Gaudet
Daniel Gaudet
DBDiane Brisson
Diane Brisson
KTKarine Tremblay
Karine Tremblay
VAVeronica J. Alexander
Veronica J. Alexander
WSWalter Singleton
Walter Singleton
JWJoseph L. Witztum
Joseph L. Witztum
The familial chylomicronemia syndrome is a genetic disorder characterized by severe hypertriglyceridemia and recurrent pancreatitis due to a deficiency in lipoprotein lipase (LPL). Currently, there are no effective therapies except for extreme restriction in the consumption of dietary fat. Apolipoprotein C-III (APOC3) is known to inhibit LPL, although there is also evidence that APOC3 increases the level of plasma triglycerides through an LPL-independent mechanism. We administered an inhibitor of APOC3 messenger RNA (mRNA), called ISIS 304801, to treat three patients with the familial chylomicronemia syndrome and triglyceride levels ranging from 1406 to 2083 mg per deciliter (15.9 to 23.5 mmol per liter). After 13 weeks of study-drug administration, plasma APOC3 levels were reduced by 71 to 90% and triglyceride levels by 56 to 86%. During the study, all patients had a triglyceride level of less than 500 mg per deciliter (5.7 mmol per liter) with treatment. These data support the role of APOC3 as a key regulator of LPL-independent pathways of triglyceride metabolism.

21 June 2012 in Gene Therapy
Verified
Journal Article
Open access
PDF file
DGDaniel Gaudet
Daniel Gaudet
JMJ Méthot
J Méthot
SDS Déry
S Déry
DBD Brisson
D Brisson
CEC Essiembre
C Essiembre
SDS van Deventer
S van Deventer
We describe the 2-year follow-up of an open-label trial (CT-AMT-011–01) of AAV1-LPLS447X gene therapy for lipoprotein lipase (LPL) deficiency (LPLD), an orphan disease associated with chylomicronemia, severe hypertriglyceridemia, metabolic complications and potentially life-threatening pancreatitis. The LPLS447X gene variant, in an adeno-associated viral vector of serotype 1 (alipogene tiparvovec), was administered to 14 adult LPLD patients with a prior history of pancreatitis. Primary objectives were to assess the long-term safety of alipogene tiparvovec and achieve a ⩾40% reduction in fasting median plasma triglyceride (TG) at 3–12 weeks compared with baseline. Cohorts 1 (n=2) and 2 (n=4) received 3 × 1011 gc kg−1, and cohort 3 (n=8) received 1 × 1012 gc kg−1. Cohorts 2 and 3 also received immunosuppressants from the time of alipogene tiparvovec administration and continued for 12 weeks. Alipogene tiparvovec was well tolerated, without emerging safety concerns for 2 years. Half of the patients demonstrated a ⩾40% reduction in fasting TG between 3 and 12 weeks. TG subsequently returned to baseline, although sustained LPLS447X expression and long-term changes in TG-rich lipoprotein characteristics were noted independently of the effect on fasting plasma TG.

1 June 2010 in Atherosclerosis Supplements
Verified
Journal Article
Closed access
DGDaniel Gaudet
Daniel Gaudet
JWJanneke de Wal
Janneke de Wal
KTKarine Tremblay
Karine Tremblay
SDStéphane Déry
Stéphane Déry
SDSander van Deventer
Sander van Deventer
JMJulie Méthot
Julie Méthot

18 February 2015 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
CMCharles Daniel Meyers
Charles Daniel Meyers
KTKarine Tremblay
Karine Tremblay
AAAhmed Amer
Ahmed Amer
JCJin Chen
Jin Chen
LJLiewen Jiang
Liewen Jiang
DGDaniel Gaudet
Daniel Gaudet
Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting in fasting chylomicronemia and severe hypertriglyceridemia. Inhibition of diacylglycerol acyltransferase 1 (DGAT1), which mediates chylomicron triglyceride (TG) synthesis, is an attractive strategy to reduce TG levels in FCS. In this study we assessed the safety, tolerability and TG-lowering efficacy of the DGAT1 inhibitor pradigastat in patients with FCS. Six FCS patients were enrolled in an open-label clinical study. Following a 1-week very low fat diet run-in period patients underwent baseline lipid assessments, including a low fat meal tolerance test. Patients then underwent three consecutive 21 day treatment periods (pradigastat at 20, 40 & 10 mg, respectively). Treatment periods were separated by washout periods of ≥4 weeks. Fasting TG levels were assessed weekly through the treatment periods. Postprandial TGs, ApoB48 and lipoprotein lipid content were also monitored. Following once daily oral dosing, steady-state exposure was reached by Day 14. There was an approximately dose proportional increase in pradigastat exposure at studied doses. Pradigastat was associated with a 41% (20 mg) and 70% (40 mg) reduction in fasting triglyceride over 21 days of treatment. The reduction in fasting TG was almost entirely accounted for by a reduction in chylomicron TG. Pradigastat treatment also led to substantial reductions in postprandial TG as well as apo48 (both fasting and postprandial). Pradigastat was safe and well tolerated, with only mild, transient gastrointestinal adverse events. The novel DGAT1 inhibitor pradigastat substantially reduces plasma TG levels in FCS patients, and may be a promising new treatment for this orphan disease. ClinicalTrials.gov identifier NCT01146522 .

1 November 2016 in Human Gene Therapy
Verified
Journal Article
Closed access
DGDaniel Gaudet
Daniel Gaudet
ESErik S. Stroes
Erik S. Stroes
JMJulie Méthot
Julie Méthot
DBDiane Brisson
Diane Brisson
KTKarine Tremblay
Karine Tremblay
MBMarco J. Bruno
Marco J. Bruno
Alipogene tiparvovec (Glybera) is a gene therapy product approved in Europe under the “exceptional circumstances” pathway as a treatment for lipoprotein lipase deficiency (LPLD), a rare genetic disease resulting in chylomicronemia and a concomitantly increased risk of acute and recurrent pancreatitis, with potentially lethal outcome. This retrospective study analyzed the frequency and severity of pancreatitis in 19 patients with LPLD up to 6 years after a single treatment with alipogene tiparvovec. An independent adjudication board of three pancreas experts, blinded to patient identification and to pre- or post-gene therapy period, performed a retrospective review of data extracted from the patients' medical records and categorized LPLD-related acute abdominal pain events requiring hospital visits and/or hospitalizations based on the adapted 2012 Atlanta diagnostic criteria for pancreatitis. Both entire disease time period data and data from an equal time period before and after gene therapy were analyzed. Events with available medical record information meeting the Atlanta diagnostic criteria were categorized as definite pancreatitis; events treated as pancreatitis but with variable levels of laboratory and imaging data were categorized as probable pancreatitis or acute abdominal pain events. A reduction of approximately 50% was observed in all three categories of the adjudicated post-gene therapy events. Notably, no severe pancreatitis and only one intensive care unit admission was observed in the post-alipogene tiparvovec period. However, important inter- and intraindividual variations in the pre- and post-gene therapy incidence of events were observed. There was no relationship between the posttreatment incidence of events and the number of LPL gene copies injected, the administration of immunosuppressive regimen or the percent triglyceride decrease achieved at 12 weeks (primary end point in the prospective clinical studies). Although a causal relationship cannot be established and despite the limited number of individuals evaluated, results from this long-term analysis suggest that alipogene tiparvovec was associated with a lower frequency and severity of pancreatitis events, and a consequent overall reduction in health care resource use up to 6 years posttreatment.